PT  - JOURNAL ARTICLE
AU  - Waltmann, Andreea
AU  - Balthazar, Jacqueline T.
AU  - Begum, Afrin A.
AU  - Hua, Nancy
AU  - Jerse, Ann E.
AU  - Shafer, William M.
AU  - ,
AU  - Hobbs, Marcia M.
AU  - Duncan, Joseph A.
TI  - <em>Neisseria gonorrhoeae</em> MtrCDE Efflux Pump During <em>In Vivo</em> Experimental Genital Tract Infection in Men and Mice Reveals the Presence of Within-Host Colonization Bottleneck
AID  - 10.1101/2023.06.23.23291824
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.23.23291824
4099  - http://medrxiv.org/content/early/2023/06/29/2023.06.23.23291824.short
4100  - http://medrxiv.org/content/early/2023/06/29/2023.06.23.23291824.full
AB  - The MtrCDE efflux pump of Neisseria gonorrhoeae exports a wide range of antimicrobial compounds that the gonococcus encounters at mucosal surfaces during colonization and infection. Here, we evaluate the role of this efflux pump system in strain FA1090 in human male urethral infection with a Controlled Human Infection Model. Using the strategy of competitive multi-strain infection with wild-type FA1090 and an isogenic mutant strain that does not contain a functional MtrCDE pump, we found that the presence of the efflux pump during human experimental infection did not confer a competitive advantage. This finding is in contrast to previous findings in female mice, which demonstrated that gonococci of strain FA19 lacking a functional MtrCDE pump had a significantly reduced fitness compared to the wild type strain in the lower genital tract of female mice. We conducted competitive infections in female mice with FA19 and FA1090 strains, including mutants that do not assemble a functional Mtr efflux pump, demonstrating the fitness advantage provided byt the MtrCDE efflux pump during infection of mice is strain dependent. Our data indicate that new gonorrhea treatment strategies targeting the MtrCDE efflux pump functions may not be universally efficacious in naturally occurring infections. Owing to the equal fitness of FA1090 strains in men, our experiments unexpectedly demonstrated the likely presence of an early colonization bottleneck of N. gonorrhoeae in the human male urethra.TRIAL REGISTRATION Clinicaltrials.gov NCT03840811.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicaltrials.gov NCT03840811.Clinical Protocols https://classic.clinicaltrials.gov/ct2/show/NCT03840811 Funding StatementThe authors and study were supported by funding from the National Institutes of Health, National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences through Grant Award Numbers U01AI114378, TL1TR002491, UL1TR001111, R01AI021150 and U19AI113170. W.M.S. is the recipient of a Senior Research Career Scientist Award from the Department of Veterans Affairs Medical Research Service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of North Carolina at Chapel Hill gave ethical approval for this work under a protocol for use of an investigational new drug (IND) that was authorized by the U.S. Food and Drug Administration. The Institutional Animal Care and Use Committee of Uniformed Services University of the Health Sciences gave ethics approval for animal work according to the guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data produced in the present study are available upon reasonable request to the authors or are contained in the manuscript